J Clin Invest. 2019 Apr 29;129(6):2175-2177. doi: 10.1172/JCI128372.
Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen-targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success.
嵌合抗原受体 (CAR) T 细胞已被证明可成功治疗某些血液系统恶性肿瘤。CAR T 细胞的疗效取决于对恶性细胞上相关靶标的识别和适当的共刺激分子。在本期 JCI 中，Cohen 等人进行了一项早期临床试验，以评估针对 B 细胞成熟抗原（BCMA）的 CAR T 细胞在难治性多发性骨髓瘤患者中的作用。接受最高剂量的 BCMA 靶向 CAR T 细胞联合淋巴细胞耗竭治疗的患者反应最大。该研究结果进一步支持了使用 BCMA 靶向 CAR T 细胞治疗骨髓瘤，并重申了 CAR T 细胞成功的空间和细胞剂量的重要性。
